Oxford Biodynamics (OBD)

 1.15p
   
  • Change Today:
      0.000p
  • 52 Week High: 34.50
  • 52 Week Low: 1.12
  • Currency: UK Pounds
  • Shares Issued: 314.14m
  • Volume: 1,205
  • Market Cap: £3.61m

Oxford Biodynamics launches collaboration to improve autism diagnosis techniques

By Duncan Ferris

Date: Monday 12 Nov 2018

LONDON (ShareCast) - (Sharecast News) - Oxford Biodynamics entered into a collaboration with Casa Sollievo della Sofferenza on Monday to research the blood-based diagnosis of Autism Spectrum Disorder (ASD).
The two parties are aiming to develop a diagnostic biomarker assay for ASD, using Oxford Biodynamics' EpiSwitch technology platform and blood samples from both autistic subjects and healthy controls provided by Casa Sollievo.

The Italian outfit is "a recognised research and biomedical institution of national importance," according to a statement released by Oxford Biodynamics.

Alexandre Akoulitchev, chief scientific officer of Oxford BioDynamics, said: "We are highly appreciative of the great expertise and ASD insights from our Italian colleagues. We strongly believe our work will help to improve the understanding of epigenetic controls and mechanisms behind this disorder."

Diagnosis remains challenging due to broad ranging symptoms and differential progression and manifestation of the disorder.

"This agreement further demonstrates rising interest in our proprietary technology, EpiSwitch, which offers results of unique value and clinical utility in biomarker discovery and disease understanding for a broad spectrum of complex indications, from immune-oncology and autoimmune conditions, to neurodegeneration, psychiatric and neurodevelopmental conditions," said Akoulitchev.

ASD is thought to be caused by a complex interaction of genetic, epigenetic and environmental factors, and represents a group of neurodevelopmental disorders, characterised by problems with social interaction, and it is estimated that approximately 1 in every 100 people in the UK has ASD.

There is no cure but speech and language therapy, occupational therapy and educational support can be deployed to improve the lives of patients, with earlier diagnosis allowing for more timely intervention.

Oxford Biodynamics' shares were down 1.80% at 206.00p at 0926 GMT

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

OBD Market Data

Currency UK Pounds
Share Price 1.15p
Change Today 0.000p
% Change 0.00 %
52 Week High 34.50
52 Week Low 1.12
Volume 1,205
Shares Issued 314.14m
Market Cap £3.61m

OBD Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

OBD Dividends

No dividends found

Trades for 22-Nov-2024

Time Volume / Share Price
08:00 945 @ 1.16p
08:00 260 @ 1.27p

Top of Page